FDA Places Clinical Holds on REGENXBIO's RGX-111 and RGX-121 Gene Therapy Programs

summarizeSummary

REGENXBIO announced that the FDA placed clinical holds on its RGX-111 and RGX-121 gene therapy programs, with the RGX-111 hold linked to a potential neoplasm in a participant.

check_boxKey Events

• Clinical Hold on RGX-111

  The FDA placed a clinical hold on the Phase I/II trial for RGX-111 (Mucopolysaccharidosis type I) following a preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant.

• Clinical Hold on RGX-121

  The FDA also placed a clinical hold on the Phase I/II/III trial for RGX-121 (Mucopolysaccharidosis type II), citing similarities in products, study populations, and shared risk, despite no neoplasm reported in RGX-121 participants.

• Investigation Ongoing

  An investigation is ongoing to determine if the serious adverse event (neoplasm) is drug-related, with preliminary genetic analysis detecting an AAV vector genome integration event associated with proto-oncogene overexpression.

• Impact on Pipeline

  These clinical holds significantly delay the development of two key gene therapy candidates for ultra-rare diseases, creating uncertainty for the company's pipeline and future commercialization efforts.

auto_awesomeAnalysis

The U.S. Food and Drug Administration (FDA) has placed clinical holds on REGENXBIO's Investigational New Drug (IND) applications for both RGX-111 (for MPS I) and RGX-121 (for MPS II). The hold on RGX-111 follows the preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a study participant. The hold on RGX-121, despite no reported neoplasm in its participants, was cited due to similarities in products, study populations, and shared risk between the clinical studies. This dual clinical hold, particularly with a potential serious adverse event in one program, represents a significant setback for the company's gene therapy pipeline, impacting development timelines and raising safety concerns that could affect investor confidence.